2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human
PAPER

1427 Regression versus persistence patterns of monosomy 7 in patients with SAMD9/SAMD9L syndromes

Maria Carla Giarratana, MD, Swarna Beesetti2, Sushree S Sahoo, PhD3, Sara Lewis, MS GC4, Enrico Attardi, MD, PhD5, Michelle Boals, NP6, Melvanique Hale, MS, BSN, RN7, Tom Michniacki, MD8, Serine Avagyan, MD, PhD9, Cristian Sotomayor, MD10, Brianna ReNay Murphy, DO11, Katie Greenwood, MD12, Jennifer Hess, DO13, Kristen Schratz, MD14, Marla Daves, MD15, Hila Dias-Polak, MD16, Carmem Bonfim, MD, PhD17, Alison A. Bertuch, MD, PhD18, Alyssa L. Kennedy, MD, PhD19, Nathan Gray, PA-C20, Marcin W Wlodarski, MD, PhD21
1 IRCCS, Istituto Giannina Gaslini, Genova, Liguria, Italy, St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 Fralin Biomedical Research Institute, FBRI Cancer Center, Virginia Tech, Washington, D.C, United States, St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children's Research Hospital, Memphis, Tennessee, United States, Tor Vergata University, Rome, Lazio, Italy
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
8 C. S. Mott Children's Hospital, Michigan Medicine, Ann Arbor, Michigan, United States
9 University of California, San Francisco, California, United States
10 Pontificia Universidad Católica de Chile, Santiago, Chile
11 Prisma Health Children's Hospital Upstate, Greenville, United States
12 Children’s Minnesota, Minneapolis, Minnesota, United States
13 Children’s Minnesota, Minneapolis, Minnesota, United States
14 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
15 St. Jude Clinic at Huntsville Hospital for Women and Children, Huntsville, Alabama, United States
16 Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel
17 Duke University School of Medicine, Durham, North Carolina, United States
18 Baylor College of Medicine, Houston, Texas, United States
19 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
20 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
21 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Background
Germline gain-of-function mutations in SAMD9 and SAMD9L (SAMD9/9L) cause bone marrow failure in which hematopoiesis is under continuous selection to eliminate the mutant allele. Loss of the mutation-bearing chromosome 7 relieves growth restriction but can progress to MDS/AML, whereas UPD7q and somatic SAMD9/9L mutations represent compensatory somatic gene rescue (SGR) events. Although monosomy 7 (-7) is traditionally considered an indication for upfront hematopoietic stem cell transplantation (HSCT), its clinical significance in SAMD9/9L syndromes remains uncertain. Importantly, -7 is not uniformly progressive in SAMD9/9L syndromes. Spontaneous disappearance of -7 can occur, with some patients remaining clinically stable for more than 20 years, while others ultimately require HSCT. Distinguishing these divergent trajectories remains a major challenge for risk stratification.

Methods
We analyzed 151 SAMD9/9L patients with -7, integrating a published retrospective cohort of 106 cases (53 SAMD9 and 53 SAMD9L) with a prospectively followed cohort of 45 patients (17 SAMD9, 28 SAMD9L)  evaluated by St. Jude Children’s Research Hospital. Serial marrow exams with karyotype, FISH, SNP array, and myeloid NGS tracked clone kinetics, SGR, myeloid driver emergence, MDS progression, and outcomes.

Results
SGR occurred in 37.7% and 44.4% of the retrospective and prospective -7 cohorts, respectively; somatic SAMD9/9L mutations were the most common SGR event (30.2% and 40.0%), followed by UPD7q (13.2% and 17.8%). Myeloid driver mutations were present in 27.4% and 20%. Across both cohorts, SGR was enriched in SAMD9L over SAMD9 (60.7% vs. 17.5%, p=0.008), supporting gene-specific clonal adaptation.

Longitudinal analysis was restricted to the prospective cohort, in which -7 was first detected at a median age of 1.58 years (range 0.1-9.7), (SAMD9: median 3.08 years, SAMD9L 1.49 years, p=0.337), underscoring the early pediatric onset of clonal disease in this syndrome. Of the 45 patients, 6 had MDS/AML or acquired myeloid driver mutations at diagnosis or within 12 months of -7 detection, 12 had insufficient longitudinal sampling, and 5 had <1 year of follow-up. The remaining 22 evaluable patients were followed for a median of 2.4 years (range 1.1-12.9). Clinically, regression vs. persistence were defined as clearance vs. maintenance of -7 at ≥ 2 consecutive evaluations over ≥1 year. Monosomy 7 regressed in 9/22 (41%) patients and persisted in 13/22 (59%). SGR showed a trend toward enrichment in the regression group compared with the persistence group (7/9, 77.8% vs 5/13, 38.5%; p=0.0991).

Median age at -7 regression was 3.6 years (range 2.37-5.87), and the largest -7 clone to disappear spontaneously measured 39% by FISH (median 20%). Among persisters, -7 clone remained stable for a median of 1.83 years (range 1.05–4.50) until last follow-up and reached up to 79.5% by FISH (median 58.3 %). Complete hematologic recovery trended higher in regressors vs. persisters (7/9, 77.8% vs. 4/13, 30.8%, p=0.08). HSCT was required in 1/9 patients with -7 regression due to transfusion-dependence, compared with 9/13 (69.2%) patients with -7 persistence (p=0.0115). Late malignant progression occurred exclusively in persisters (3/13, 23%), and was associated with acquisition of SETBP1, ASXL1, RUNX1, and EZH2 mutations at a median of 2 years (range 1.17-3) after first -7 detection. Across the full prospective cohort, 9/45 patients (20%) developed malignant progression (myeloid driver mutations and/or MDS/AML) at any time point, over 109.2 cumulative person-years. Overall survival was 43/45 (95.6%), with both deaths related to HSCT.

Conclusions
Monosomy 7 regression in SAMD9/9L syndrome can occur in early childhood and is associated with transplant-free hematologic recovery. In contrast, persistent -7 carries a risk of myeloid driver acquisition (~23% of longitudinally observed patients). These findings support a risk-adapted approach in which young -7 cases without high-risk features undergo close molecular surveillance, reserving HSCT for those with persistent -7 and evidence of malignant progression.

Enrico Attardi, MD, PhD: No relevant conflicts of interest to declare.